A note for UK readers

This page explains India’s system. Its licences, funding rules and prescribing criteria do not determine access in the UK.

Can a weight-loss advertisement replace specialist assessment?

No. Government guidance emphasises the specialist-prescribing conditions attached to these medicines and action against unauthorised sale and promotion.

Read the actual approval

CDSCO records include semaglutide injections approved for chronic weight management in defined adult groups. An entry for a diabetes product, a trial permission or a committee recommendation is a different document and should not be presented as a new obesity marketing approval.

Prescriber conditions are specific

The government's March 2026 communication reiterates prescribing by endocrinologists and internal-medicine specialists, with cardiologists for some indications. Ask the treating service to confirm the conditions applying to the exact medicine it proposes.

Approval does not settle the bill

The sources reviewed do not establish universal public or insurance funding for GLP-1 obesity treatment. Request an individual coverage decision. New brands or competition alone cannot establish what a patient will pay for continuing care.

Put lower-price headlines in context

Indian competition or launch prices do not establish that a medicine is authorised, available or cheaper within a UK care pathway. UK readers should compare verified UK prescriptions and follow-up in GBP, rather than convert an overseas medicine-only price.

Keep these four questions separate

Access

Indian approval and specialist-prescribing conditions

Funding

Individual public-service or insurance verification needed

Cost context

INR launch prices do not establish UK savings

Regulatory source

CDSCO and state drug-control authorities

Compare health systems ↗
Follow the evidence

Sources & further reading

Sources checked . These links support the information above; they do not imply endorsement of this website.

  1. CDSCO: biological medicines approved for import and marketing
  2. Government of India: prescribing conditions and unauthorised GLP-1 sales
A note on this guide

Written for a UK audience by the Health Comparisons editorial team. This page is an information resource and has not been presented as a clinician’s personal recommendation. Discuss treatment decisions with your prescriber.

Read our editorial standards →